Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
PRJ-13024 by Guangzhou Yinming Biomedical Technology for Cutaneous Squamous Cell Carcinoma (cSCC): Likelihood of Approval
PRJ-13024 is under clinical development by Guangzhou Yinming Biomedical Technology and currently in Phase II for Cutaneous Squamous Cell Carcinoma...
Data Insights
PRJ-13024 by Guangzhou Yinming Biomedical Technology for Prostate Cancer: Likelihood of Approval
PRJ-13024 is under clinical development by Guangzhou Yinming Biomedical Technology and currently in Phase II for Prostate Cancer. According to...